1. Driver mutations associated with signatures of platinum sensitivity in germ cell tumors
- Author
-
Yun Cheng Sawa, Liwei Jia, Harris Krause, Margaret Meagher, Frederick Millard, Andrew Elliott, John T. Lafin, Christina Jamieson, Emmanuel S. Antonarakis, Anishka D’Souza, Krinio Giannikou, James F. Amatruda, Siamak Daneshmand, Rana R. McKay, Matthew Oberley, Chadi Nabhan, and Aditya Bagrodia
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract We sought to evaluate the genomic and transcriptomic landscapes in primary and metastatic germ cell tumors (GCTs; N = 138) to uncover factors that drive cisplatin resistance. Prevalence was calculated for platinum-resistant alterations (PRAs; KRAS, TP53, and KIT mutations, and MDM2 amplification) and high copy number amplifications (CNA ≥ 6 copies). Tumors were designated as chemo-naïve (PreC, N = 66) or post-chemotherapy (PostC, N = 17). A transcriptomic signature associated with platinum sensitivity (PSS, high suggests increased sensitivity) was applied. KIT mutations were observed in 14.5% of primary versus 1.8% of met and 0% of lymph. TP53 mutations were identified in 10% of primary GCTs versus 17% of met and 16.7% of lymph. MDM2 CNAs were similar between sites. PRA-positive PreC GCTs had significantly lower average PSS scores compared to PRA-negative tumors. Lower PSS scores in chemo-naïve tumors were associated with PRAs, suggesting a potential mechanism for platinum resistance.
- Published
- 2024
- Full Text
- View/download PDF